Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dawn E Quelle

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
Cell Cycle (Georgetown, Tex.)|March 14, 2014
Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53Sara M Reed, Jussara Hagen, Van S Tompkins, et al.
International Journal of Molecular Sciences|June 2, 2021
RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent MannerJordan L Kohlmeyer, Courtney A Kaemmer, Shaikamjad Umesalma, et al.
Cancers|October 23, 2021
Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic TargetsChandra K Maharjan, Po Hien Ear, Catherine G Tran, et al.
International Journal of Molecular Sciences|April 30, 2020
CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic TargetsJordan L Kohlmeyer, David J Gordon, Munir R Tanas, et al.
Molecular and Cellular Biology|February 3, 2005
Nucleophosmin (B23) targets ARF to nucleoli and inhibits its functionChandrashekhar Korgaonkar, Jussara Hagen, Van Tompkins, et al.
Experimental Cell Research|April 1, 2009
Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activitiesAnne di Tommaso, Jussara Hagen, Van Tompkins, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|September 30, 2024
The University of Iowa Neuroendocrine Tumor ClinicJames R Howe, Yusuf Menda, Chandrikha Chandrasekharan, et al.
Oncotarget|January 18, 2021
Combination therapies for MPNSTs targeting RABL6A-RB1 signalingJordan L Kohlmeyer, David J Gordon, Munir R Tanas, et al.
Scientific Reports|August 17, 2017
Myst2/Kat7 histone acetyltransferase interaction proteomics reveals tumour-suppressor Niam as a novel binding partner in embryonic stem cellsMercedes Pardo, Lu Yu, Shihpei Shen, et al.
Plos One|February 20, 2020
Validating indicators of CNS disorders in a swine model of neurological diseaseVicki J Swier, Katherine A White, David K Meyerholz, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Cell Cycle (Georgetown, Tex.)|March 14, 2014
Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53Sara M Reed, Jussara Hagen, Van S Tompkins, et al.
International Journal of Molecular Sciences|June 2, 2021
RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent MannerJordan L Kohlmeyer, Courtney A Kaemmer, Shaikamjad Umesalma, et al.
Cancers|October 23, 2021
Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic TargetsChandra K Maharjan, Po Hien Ear, Catherine G Tran, et al.
International Journal of Molecular Sciences|April 30, 2020
CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic TargetsJordan L Kohlmeyer, David J Gordon, Munir R Tanas, et al.
Molecular and Cellular Biology|February 3, 2005
Nucleophosmin (B23) targets ARF to nucleoli and inhibits its functionChandrashekhar Korgaonkar, Jussara Hagen, Van Tompkins, et al.
Experimental Cell Research|April 1, 2009
Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activitiesAnne di Tommaso, Jussara Hagen, Van Tompkins, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|September 30, 2024
The University of Iowa Neuroendocrine Tumor ClinicJames R Howe, Yusuf Menda, Chandrikha Chandrasekharan, et al.
Oncotarget|January 18, 2021
Combination therapies for MPNSTs targeting RABL6A-RB1 signalingJordan L Kohlmeyer, David J Gordon, Munir R Tanas, et al.
Scientific Reports|August 17, 2017
Myst2/Kat7 histone acetyltransferase interaction proteomics reveals tumour-suppressor Niam as a novel binding partner in embryonic stem cellsMercedes Pardo, Lu Yu, Shihpei Shen, et al.
Plos One|February 20, 2020
Validating indicators of CNS disorders in a swine model of neurological diseaseVicki J Swier, Katherine A White, David K Meyerholz, et al.
Pageof 6